CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

about

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Item

http://www.wikidata.org/entity/Q53828417

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@en

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@nl

type

Item

label

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@en

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@nl

prefLabel

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@en

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@nl

P1476

CHOP versus GEM-P in previousl ...... randomised, open-label trial.

@en

P2093

Adam Forbes

http://www.w3.org/2001/XMLSchema#string

Alistair Hart

http://www.w3.org/2001/XMLSchema#string

Ayoma D Attygalle

http://www.w3.org/2001/XMLSchema#string

Bhupinder Sharma

http://www.w3.org/2001/XMLSchema#string

Clare Peckitt

http://www.w3.org/2001/XMLSchema#string

Deborah Turner

http://www.w3.org/2001/XMLSchema#string

Eliza A Hawkes

http://www.w3.org/2001/XMLSchema#string

Ian Chau

http://www.w3.org/2001/XMLSchema#string

Imene Zerizer

http://www.w3.org/2001/XMLSchema#string

Jacqueline Oates

http://www.w3.org/2001/XMLSchema#string

P2860

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.

Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.

Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.

Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

P304

e190-e200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S2352-3026(18)30039-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29703335

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

5946805

http://www.w3.org/2001/XMLSchema#string